A clinical review of Adderall XR (mixed amphetamine salts) microdosing protocols, standard dosing evidence, pharmacokinetics, and prescribing considerations backed by primary literature.
A complete clinical guide to AndroGel (testosterone gel 1% and 1.62%) caregiver administration for men 65 and older, covering application technique, transfer prevention, safety monitoring, and dose adjustment.
A guide to AndroGel (testosterone gel 1%/1.62%) use in men aged 65 and older, covering FDA labeling, off-label considerations, the TTrials findings, cardiovascular and hematologic risks, dosing, and monitoring protocols.
AndroGel (testosterone gel 1%/1.62%) is FDA-approved for adult men only. This evidence-based guide covers the rare off-label scenarios where topical testosterone is considered in children under 12, including microphallus, delayed puberty, and accidental exposure risks.
A guide covering AOD-9604 (HGH fragment 176-191) use in 12-to-17-year-olds, including effects on energy, cognition, physical activity, school performance, and safety signals parents and providers should know.
AOD-9604 (HGH fragment 176-191) has no approved pediatric indication. This HealthRX.com guide covers why clinicians withhold it from children under 12, what the evidence base looks like, and how to support healthy weight and activity in this age group.
A guide covering BPC-157 use in adolescents ages 12 to 17, the evidence (and gaps) around this peptide, and how to safely transfer care to an adult provider without losing treatment continuity.
What is known about BPC-157 in older adults? Examine geriatric evidence gaps, animal pharmacokinetics, kidney-function assumptions, and interaction claims.
What is missing from pediatric BPC-157 research, why adult or animal doses cannot answer child-specific questions, and what to do after an exposure.
Bremelanotide (Vyleesi) is FDA-approved only for premenopausal adults. This clinical guide explains why it has no established role in pediatric patients under 12, what parents and clinicians should know about safety, and how to approach school and activity planning when a household member uses it.
A clinical review of tadalafil's effects on adolescent development, covering approved pediatric indications, hormonal interactions, bone and cardiovascular safety, and what parents and prescribers need to know.
A guide to off-label tadalafil use in children under 12, covering pulmonary arterial hypertension, dosing data, trial evidence, safety signals, and how prescribers manage a drug with no FDA pediatric label for this age group.
A guide to tadalafil use in pediatric patients under age 12, covering approved indications, dosing evidence, safety monitoring, and structured transition planning for adolescent and adult care handoff.
A look at how CJC-1295 (modified GRF) affects adolescent development, why the 12-17 age range carries unique physiological risks, and what current endocrinology guidelines say about growth-hormone secretagogues in minors.
What parents, coaches, and clinicians need to know about CJC-1295 use in teens aged 12 to 17, covering academic performance, sports participation, sleep, safety, and regulatory status.
A clinical review of CJC-1295 (modified GRF) use in children under 12, covering growth hormone axis physiology, safety data, regulatory status, and why this peptide has no established role in pediatric medicine.
A clinical overview of CJC-1295 (modified GRF) off-label use in children under 12, covering regulatory status, pharmacology, safety data gaps, and the current standard of care for pediatric growth hormone deficiency.
A clinical deep-dive into how dulaglutide (Trulicity) affects growth, puberty, bone density, and metabolic development in adolescents ages 12 to 17, including trial data, dosing, and monitoring guidance.
A clinical guide to using Trulicity (dulaglutide) safely in adults aged 65 and older, covering physical activity, cognitive engagement, fall risk, dosing schedules, and daily-life planning.
A clinician-focused guide to using dulaglutide (Trulicity) in geriatric patients aged 65 and older, covering dose selection, safety considerations, renal function, polypharmacy, and care-transition planning.
Complete caregiver guide to administering Trulicity (dulaglutide) to children under age 12, including injection technique, dosing schedules, storage, side-effect management, and when to call the prescriber.
A clinical guide to managing dulaglutide therapy in pediatric patients under age 12 with type 2 diabetes, covering FDA approval status, dosing, monitoring, and the structured transition to adult endocrinology care.
A clinical deep-dive into dutasteride (Avodart) use in adolescents aged 12-17, covering hormonal development, DHT suppression risks, sexual maturation, bone health, fertility, and FDA prescribing guidance.
A guide to how dutasteride (Avodart) affects cognitive function, driving, physical activity, and daily scheduling in adults aged 65 and older, with primary-source citations throughout.
A guide to how enclomiphene citrate affects cognitive performance, driving, exercise capacity, and daily activities in men aged 65 and older, with dosing context and safety data.
A clinically grounded guide to epitalon use in adults aged 65 and older, covering cognitive engagement, physical activity compatibility, dosing considerations, and the telomere science behind this tetrapeptide.
Complete caregiver guidance on administering finasteride to adolescents aged 12 to 17, including dosing, safety monitoring, pregnancy exposure risks, and when to contact a prescriber.
A guide to off-label finasteride use in geriatric patients (65+), covering BPH, prostate cancer prevention, androgenic alopecia, and the unique safety considerations for older adults.
A clinical guide to finasteride use in geriatric patients (65+), covering cognitive safety, physical activity interactions, driving, fall risk, and quality-of-life considerations backed by primary-source evidence.
A guide to finasteride use in geriatric patients (65+), covering pharmacokinetics, BPH and hair-loss dosing, drug interactions, PSA monitoring, sexual side-effect risk, and practical transition-of-care checklists.
A clinical review of GHK-Cu (copper tripeptide) use in adolescents aged 12 to 17, covering wound healing biology, copper metabolism, safety data gaps, and why physicians generally advise against peptide supplementation during active development.
A guide to the off-label use of copper tripeptide GHK-Cu in adolescents ages 12 to 17, covering pharmacology, safety data, regulatory status, and clinical considerations.
A guide to GHK-Cu (copper tripeptide) off-label use in geriatric patients aged 65+, covering mechanisms, published trial data, dosing considerations, safety, and what to discuss with your prescriber.
Everything families and clinicians need to know about ipamorelin use in adolescents ages 12 to 17, including dosing considerations, growth-plate safety, and a structured transition to adult care protocols.
A guide to ipamorelin acetate use in pediatric patients under age 12, covering growth hormone physiology, developmental risks, regulatory status, and the clinical evidence base.
A clinical guide to isotretinoin use in adolescents ages 12 to 17, covering iPLEDGE requirements, dosing, lab monitoring, mental health considerations, and how to plan a safe handoff to adult dermatology care.
A guide for caregivers managing isotretinoin therapy in patients aged 65 and older, covering iPLEDGE requirements, dose adjustments, drug interactions, and monitoring protocols specific to the geriatric population.
A clinically detailed guide to isotretinoin use in adults aged 65 and older, covering iPLEDGE enrollment, dose adjustments, drug interactions, organ-system monitoring, and the transition from pediatric or young-adult dermatology care to geriatric-focused management.
A guide covering isotretinoin use in children under 12, including dosing, iPLEDGE requirements, monitoring protocols, and how to transition young patients safely to adult dermatology care.
A clinical review of off-label liraglutide use in geriatric patients (65+), covering evidence from major trials, age-specific dosing considerations, cardiovascular data, and safety signals unique to older adults.
A clinical guide for patients and providers on using liraglutide (Victoza, Saxenda) in adults aged 65+, including dosing adjustments, safety considerations, and how to manage care transitions from geriatric to adult medicine.
A guide covering liraglutide use in pediatric patients under age 12, current FDA approval status, dosing evidence, and how to manage the transition to adult endocrinology or obesity medicine care.
A comprehensive clinical review of low-dose naltrexone (LDN) use in pediatric patients under age 12, covering neurodevelopmental effects, immune modulation, dosing considerations, and the current state of evidence.
A guide to off-label metformin use in geriatric patients aged 65 and older, covering longevity, cancer prevention, cognitive protection, PCOS, and weight management, with current dosing guidance and renal safety thresholds.
A clinical guide to metformin use in geriatric patients covering cognitive engagement, physical activity, exercise-related lactic acidosis risk, renal monitoring, and dose adjustments for adults 65 and older.
A guide to metformin's developmental effects in children under 12, covering growth, cognition, puberty, and B12 status, with citations from clinical trials and FDA labeling.
A clinical deep-dive into off-label metformin use in children younger than 12, covering evidence, dosing, risks, and when prescribers consider it appropriate.
A guide for caregivers managing MK-677 (ibutamoren) use in adolescents aged 12-17, covering dosing, timing, monitoring, side effects, and when to contact a provider.
Review pediatric ibutamoren and LUM-201 research in growth hormone deficiency, and why short-term hormone responses do not establish height or bodybuilding benefits.
What adolescents, parents, and clinicians need to know about MK-677 (ibutamoren) use during the school years, including effects on cognition, sleep, sports eligibility, and physical activity safety.
A guide to MK-677 (ibutamoren) use in adolescents ages 12 to 17, covering growth hormone axis effects, safety concerns, and the critical steps for transitioning young patients to adult endocrine care.
MK-677 has no FDA approval and raises congestive heart failure risk in older adults, plus higher blood sugar and insulin resistance. See the trial data.
A cautious clinical review of MK-677 (ibutamoren) and pediatric use in children under 12, covering what is and is not known about growth hormone axis effects, IGF-1 elevation, insulin sensitivity, and why no regulatory body has approved ibutamoren for this age group.
MOTS-c is an experimental mitochondrial peptide with zero pediatric clinical trial data. This evidence review explains why off-label use in children under 12 carries serious unknowns and what the current science actually shows.
A guide to MOTS-c mitochondrial peptide in pediatric patients under 12, covering current evidence, safety data, regulatory status, and what a structured transition to adult endocrinology care looks like.
A guide to managing tirzepatide (Mounjaro) in adolescents aged 12-17, covering school schedules, injection timing, physical activity, nutrition during sports, and how to communicate with teachers and coaches.
Step-by-step caregiver guidance for administering Mounjaro (tirzepatide) to adults aged 65 and older, including dose escalation, injection technique, hypoglycemia monitoring, and age-specific safety considerations.
A clinical guide to using Mounjaro (tirzepatide) off-label in geriatric patients aged 65+, covering efficacy data, dose titration, sarcopenia risk, renal considerations, and prescriber decision frameworks.
Tirzepatide (Mounjaro) is not approved for children under 12. This clinical guide covers the evidence gap, off-label risk framework, current pediatric obesity guidelines, and what families should ask their physician.
A detailed clinical review of NMN and NR supplementation in adolescents aged 12 to 17, covering NAD+ biology, puberty, brain development, safety data, and why no regulatory body currently recommends these supplements for this age group.